Dr. Reshma Kewalramani: The India-Connected Physician Leading a New Era of Biotechnology
From medical training in Boston to the corner office at Vertex Pharmaceuticals, Dr. Reshma Kewalramani has built a career at the intersection of medicine, biotechnology and global leadership. Her journey offers a larger lesson for the Indian diaspora: scientific leadership is increasingly about connecting clinical knowledge, technology and the ability to turn breakthrough research into medicines.
There are many ways to tell the story of Dr. Reshma Kewalramani.
One is to begin with the title: President and Chief Executive Officer of Vertex Pharmaceuticals, one of the world’s leading biotechnology companies.
Another is to begin with the milestone: when she became Vertex’s CEO in April 2020, she became the first woman to lead a large biotechnology company as its CEO, according to Boston University.
But neither is quite as revealing as beginning with her training.
Kewalramani is a physician.
She trained in internal medicine and nephrology before moving into pharmaceutical research and development, eventually becoming a senior R&D leader at Amgen and then joining Vertex in 2017 as its Chief Medical Officer.
That combination—doctor, drug-development executive and biotechnology leader—helps explain why her career has become significant far beyond a conventional corporate success story.
It sits at the intersection of Indian diaspora achievement, American scientific enterprise and some of the most consequential developments in modern medicine.
From medicine to biotechnology leadership
Kewalramani graduated from Boston University’s seven-year Liberal Arts/Medical Education Program in 1998, earning both her undergraduate and medical degrees. She subsequently trained in internal medicine and nephrology and developed a career in clinical medicine and pharmaceutical development.
Her transition into industry was not a rejection of medicine.
It was an expansion of its scale.
A physician may treat patients one at a time.
A successful drug-development programme can potentially affect thousands or millions of patients.
That is one of the defining attractions—and responsibilities—of pharmaceutical research.
Kewalramani spent more than a decade at Amgen in research and development leadership roles before joining Vertex as Chief Medical Officer in 2017.
Two years later, Vertex announced that she would succeed Jeffrey Leiden as president and CEO from April 1, 2020.
She took over at a company that already had a remarkable position in cystic fibrosis medicine.
Her challenge was not simply to protect that franchise.
It was to broaden Vertex into a biotechnology company capable of producing new classes of transformative medicines.
The CRISPR moment
That strategy became particularly visible with CASGEVY.
In December 2023, the US Food and Drug Administration approved CASGEVY, an exagamglogene autotemcel therapy developed by Vertex in partnership with CRISPR Therapeutics, for patients aged 12 and older with sickle cell disease and recurrent vaso-occlusive crises.
It was the first CRISPR/Cas9 gene-editing therapy approved in the United States.
That distinction is important.
CRISPR had existed as a revolutionary scientific tool for years. The difficult step was converting that biological insight into an approved therapy that could be manufactured, administered and monitored in actual patients.
CASGEVY represents that transition from laboratory technology to medicine.
Vertex subsequently received FDA approval for CASGEVY in transfusion-dependent beta-thalassemia as well. The FDA’s current information lists CASGEVY for sickle cell disease and transfusion-dependent beta-thalassemia, with the approved age range having subsequently expanded.
Kewalramani has publicly described the approval as a historic moment for patients and medicine.
But the achievement belongs to a much larger scientific ecosystem.
CRISPR Therapeutics, Vertex scientists, clinical investigators, manufacturing specialists, regulatory teams and—most importantly—patients who participated in clinical studies were all part of the development process.
That distinction matters when celebrating leadership.
A CEO does not personally invent a gene-editing therapy.
The CEO’s role is to help create the organisation, capital allocation, scientific strategy and execution environment in which such discoveries can become medicines.
From cystic fibrosis to a broader platform
Vertex’s history is deeply connected with cystic fibrosis.
The company developed medicines designed to address the underlying cause of the disease rather than simply treating individual symptoms.
Kewalramani inherited and expanded that scientific platform.
Vertex’s portfolio has included medicines such as TRIKAFTA and ALYFTREK, alongside CASGEVY and programmes in other serious diseases.
In its 2025 corporate outlook, Vertex said it was continuing to broaden its revenue base, advance multiple potentially transformative medicines and expand its global commercial and clinical footprint.
That diversification is strategically important.
Biotechnology companies face a brutal reality: even a successful medicine has a finite commercial life, while scientific failure is always possible.
A company cannot depend indefinitely on one therapeutic area.
The ability to repeatedly move promising science through clinical development and regulatory review therefore becomes one of the industry’s most valuable capabilities.
Then came a different kind of pain medicine
In January 2025, the FDA approved JOURNAVX (suzetrigine) for adults with moderate-to-severe acute pain.
The significance goes beyond another product launch.
The FDA described Journavx as the first approved drug in a new class of non-opioid pain medicines. It works by targeting a sodium-channel pathway involved in transmitting pain signals in the peripheral nervous system.
For a company historically associated with cystic fibrosis, this represents a major expansion.
For the wider medical system, it also addresses a longstanding problem: finding effective ways to treat acute pain without relying exclusively on opioids.
That does not mean Journavx eliminates the need for opioids or is appropriate for every patient.
It means the therapeutic toolbox has become larger.
And expanding that toolbox is one of the clearest ways biotechnology can have an impact beyond the laboratory.
Why her Indian connection matters
It matters because she represents a generation of diaspora professionals who have built careers by operating at the highest levels of global institutions while retaining an important connection to their Indian heritage.
That distinction is increasingly important.
The Indian diaspora’s global contribution cannot be reduced to remittances or the number of people holding senior corporate positions.
Its influence also appears in science, medicine, technology, entrepreneurship, research and public health.
Kewalramani’s career illustrates the scientific side of that diaspora story.
Her professional journey has moved through institutions that sit at the heart of American medicine and biotechnology, while her background remains part of the broader Indian-origin success story in the United States.
And there is a useful lesson here for young Indians considering careers abroad.
Global success does not necessarily require abandoning one’s original professional identity.
A physician can become a biotechnology executive without ceasing to be a physician at heart.
A scientist can become a business leader without treating science as secondary.
The most valuable careers may increasingly belong to people who can move comfortably between disciplines.
The leadership lesson is bigger than gender
The historic significance of Kewalramani becoming the first female CEO of a large biotechnology company should not be minimised.
Biotechnology has long employed large numbers of women scientists and physicians. Leadership representation, however, has historically lagged behind participation.
Her appointment therefore carried symbolic importance.
But there is a danger in making the story only about gender.
Kewalramani’s professional trajectory also illustrates a deeper shift in corporate leadership.
Modern life-sciences companies need executives who understand science, medicine, regulation, clinical development, commercial strategy and organisational leadership.
A purely financial or purely operational approach is insufficient when the underlying product is a biological intervention that must survive years of scientific and regulatory scrutiny.
Her medical background gives her a perspective that is particularly relevant to that environment.
The difficult side of breakthrough medicine
The success story should nevertheless be accompanied by realism.
Gene-editing therapies are scientifically extraordinary, but they can be complex to manufacture and administer.
CASGEVY is a personalised, one-time cell therapy involving collection and modification of a patient’s own blood stem cells before they are returned to the patient.
The FDA has also identified significant risks and adverse reactions associated with the treatment, including warnings related to neutrophil engraftment failure, delayed platelet engraftment, hypersensitivity and the possibility of unintended genomic changes.
This is why calling a new therapy “revolutionary” should never mean calling it risk-free.
Breakthrough medicine is still medicine.
Patients need specialist care, appropriate eligibility assessment, long-term monitoring and access systems capable of handling sophisticated therapies.
The scientific achievement and the healthcare-access challenge exist simultaneously.
What the diaspora can learn from her journey
Perhaps the most valuable part of Kewalramani’s story is not the title on her business card.
It is the sequence.
Medical education → clinical expertise → pharmaceutical R&D → biotechnology leadership → global drug development.
That path demonstrates that careers do not have to remain inside the boundaries of the degree with which they begin.
For Indian students and young professionals abroad, that is a particularly useful lesson.
The diaspora increasingly occupies fields where disciplines overlap.
Doctors are moving into biotech.
Engineers are entering healthcare.
Scientists are becoming entrepreneurs.
Data specialists are transforming drug discovery.
Business leaders are learning enough science to make strategic decisions.
The strongest global organisations increasingly need these hybrids.
From immigrant success story to global scientific story
There is a familiar way of describing successful Indians abroad: the immigrant who worked hard, rose through the ranks and reached the top.
Kewalramani’s career deserves a more ambitious description.
She is part of a generation of Indian-connected professionals who are helping shape what the world’s most advanced institutions actually do.
At Vertex, that means leading an organisation working on gene editing, genetic disease, pain and other serious conditions.
Her story is therefore not only about representation.
It is about capability.
The most meaningful diaspora success stories are not necessarily the ones with the biggest titles.
They are the ones in which a person’s expertise becomes part of something larger than their own career.
For Kewalramani, that larger story is medicine.
And for the Indian diaspora, it is a reminder that global influence is increasingly measured not simply by where people come from or where they live—but by what they help the world build, discover and deliver.
World Beyond the News
Birds Can Navigate Using Earth’s Magnetic Field
Several bird species can sense Earth’s magnetic field, helping them navigate during long-distance migration.
Fermentation Is a Global Food Tradition
People across continents have used fermentation for centuries to preserve food and create distinctive flavours.
Modern Batteries Store Energy Chemically
Rechargeable batteries repeatedly move ions between electrodes, allowing electrical energy to be stored and released.
Why Songs Become Global Hits
Streaming platforms, short-form video, playlists and international collaborations can rapidly carry music across borders.
